Georgia CTSA Leader Presents Benefits to Cost-Informed Decision Making in Treating Patients with HFrEF
The main outcome of trial, cost-informed decision-making, occurred in 49% of encounters with checklist only control group compared with 68% of encounters in the out of pocket cost group. Other differences were also observed. “These hypothesis-generating findings suggest cost disclosure may reduce ‘contingency planning’ and increase the extent to which patients are taking the medications decided upon,” said Neal W. Dickert, MD, PhD, FACC, Georgia CTSA Network Capacity Director, Emory.